Ferrous Bisglycinate as a well-tolerated API against Iron Deficiency Anemia
Dr. Paul Lohmann® is the world's first manufacturer of Ferrous Bisglycinate as an active pharmaceutical ingredient (API), which is available including the API documentation (DMF/ASMF) for the registration of a drug with the health authorities.
Ferrous Bisglycinate is a fully reacted Iron Salt based on glycine with a low heavy metal content and an improved solubility and dissolution profile.1 The glycine chelate structure protects the highly reactive Iron from redox reactions in the gastrointestinal tract and thus prevents unpleasant side effects such as epigastric pain, nausea, vomiting and abdominal cramps.2 Due to its high bioavailability and tolerance during use, Ferrous Bisglycinate is ideally suited as an API for the treatment of Iron deficiency anemia and for the prevention of Iron status disorders in pregnant women and breastfeeding mothers.3
References:
1 Name, J. J., et al. Iron Bisglycinate Chelate and Polymaltose Iron for the Treatment of Iron Deficiency Anemia: A Pilot Randomized Trial; 2018, 14(4), 261-268.
2. Ferrari, P., et al. Treatment of mild non-chemotherapy-induced iron deficiency anemia in cancer patients: comparison between oral ferrous bisglycinate chelate and ferrous sulfate. Biomedicine & Pharmacotherapy, 2012, 66(6), 414-418.
3. Soppi, E. T. Iron deficiency without anemia – a clinical challenge, Clinical Case Reports, 2018, 6(6), 1082-1086.
Related News
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News Say hello to the CPHI Exhibitor Spotlight!
We’re kicking off a brand-new series where we shine the spotlight on some of the amazing companies gearing up to shake things up at CPHI Americas 2025 this May! The first company in our spotlight is TAPI, who are set to make a splash at its ve... -
News CPHI Podcast Series: How to build a successful CDMO partnership
The latest in our series for the CPHI Podcast Series focuses on partnerships, specifically those between pharma companies and CDMOs. Expert Christine Fürst from Vetter comments on how to make successful and lasting partnerships in the industr... -
News How GLP-1 agonists are reshaping drug delivery innovations
GLP-1 agonist drug products like Ozempic, Wegovy, and Mounjaro have taken the healthcare industry by storm in recent years. Originally conceived as treatment for Type 2 diabetes, the weight-loss effects of these products have taken on unprecedented int... -
News 2025 Pharma Trends Outlook: Collaborative Pharma – A New Era of Supply Chains
A new year, a new Pharma Trends Outlook report! The 2025 Pharma Trends Outlook report examines key changes expected in the pharmaceutical industry for the coming year, particularly in regards to the supply chain.
-
.png)
News Women in Pharma: Our hopes for 2025 and beyond
Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the... -
News Closing 2024 with Editors' picks of top articles from the past year
Coming to the end of 2024 and it’s certainly been a busy year, for CPHI and for the rest of the pharmaceutical and healthcare industry. Topics of conversation throughout the last 12 months have been varied, touching on the technical, to the polit...